Tech Company Financing Transactions

ViaCyte Funding Round

Bain Capital Life Sciences, RA Capital and Sanderling Ventures joined a $80 million Series D funding round for ViaCyte. The financing round was announced on 11/30/2018.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

3550 General Atomics Ct.
San Diego, CA 92121
USA

Phone

(858) 455-3708

Website

www.viacyte.com

Email Address

[email protected]

Overview

ViaCyte is a preclinical therapeutic company focused on diabetes. Our therapy is based on pancreatic beta cell progenitors (Pro-Islet) derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Michael Yang

        

Chief Financial Officer

Brittany Bradrick

        

Chief Medical Officer

Howard Foyt

        

Chief Scientific Officer

Kevin D'Amour

        

Chief Technical Officer

Steve White

        

Vice President

Manasi Jaiman

        

VP - Finance

Anne Sandan

        

VP - General Counsel

Liz Bui

        

VP - Regulatory Affairs

Steve Kradjian

        

Browse more venture capital transactions:

Prev: 11/30/2018: RAGS venture capital transaction
Next: 11/30/2018: Amitree venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary